Celldex Historical Income Statement
| CLDX Stock | USD 38.53 1.10 2.78% |
Historical analysis of Celldex Therapeutics income statement accounts such as Selling General Administrative of 29.4 M, Total Revenue of 7.6 M or Gross Profit of 2.6 M can show how well Celldex Therapeutics performed in making a profits. Evaluating Celldex Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Celldex Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Celldex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Celldex Therapeutics is a good buy for the upcoming year.
Celldex |
About Celldex Income Statement Analysis
Celldex Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Celldex Therapeutics shareholders. The income statement also shows Celldex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Celldex Therapeutics Income Statement Chart
Celldex Therapeutics Income Statement is one of the three primary financial statements used for reporting Celldex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Celldex Therapeutics revenue and expense. Celldex Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Celldex Therapeutics' Total Revenue is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 156.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2.6 M in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts Celldex Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Celldex Therapeutics. It is also known as Celldex Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Celldex Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Total Revenue is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 156.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2.6 M in 2024.
| 2023 | 2024 (projected) | Extraordinary Items | 17.2M | 15.3M | Reconciled Depreciation | 2.9M | 3.1M |
Celldex Therapeutics income statement Correlations
Click cells to compare fundamentals
Celldex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Celldex Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (3.1M) | 25.2M | 3.7M | 13.4M | 3.0M | 2.6M | |
| Selling General Administrative | 15.4M | 14.5M | 20.5M | 27.2M | 30.9M | 29.4M | |
| Total Revenue | 3.6M | 7.4M | 4.7M | 2.4M | 6.9M | 7.6M | |
| Gross Profit | (39.1M) | (35.1M) | 1.6M | 957K | 3.9M | 2.6M | |
| Other Operating Expenses | 58.1M | 57.0M | 73.8M | 109.5M | 148.9M | 156.4M | |
| Operating Income | (55.0M) | (63.4M) | (71.2M) | (115.2M) | (142.0M) | (134.9M) | |
| Ebit | (55.0M) | (63.4M) | (71.2M) | (115.2M) | (142.0M) | (134.9M) | |
| Ebitda | (58.2M) | (38.2M) | (67.6M) | (101.9M) | (139.0M) | (132.1M) | |
| Total Operating Expenses | 58.1M | 57.0M | 73.8M | 109.5M | 145.9M | 153.2M | |
| Income Before Tax | (50.9M) | (60.9M) | (70.7M) | (112.3M) | (141.4M) | (134.4M) | |
| Total Other Income Expense Net | 4.2M | 2.4M | 505K | 2.9M | 613K | 643.7K | |
| Net Income | (50.4M) | (59.8M) | (70.5M) | (122.8M) | (141.4M) | (134.4M) | |
| Income Tax Expense | (506K) | (1.2M) | (227K) | 10.5M | 9.4M | 9.9M | |
| Cost Of Revenue | 42.7M | 42.5M | 3.1M | 1.4M | 3.0M | 2.9M | |
| Research Development | 42.7M | 42.5M | 53.3M | 82.3M | 115.0M | 120.8M | |
| Net Income From Continuing Ops | (50.9M) | (59.8M) | (70.5M) | (112.3M) | (124.6M) | (130.8M) | |
| Non Recurring | 109.7M | 1.8M | 18M | 3.5M | 4.0M | 3.8M | |
| Non Operating Income Net Other | 4.5M | 4.2M | 2.4M | 505K | 580.8K | 551.7K | |
| Net Income Applicable To Common Shares | (50.9M) | (59.8M) | (70.5M) | (112.3M) | (101.1M) | (106.1M) | |
| Reconciled Depreciation | 4.9M | 3.9M | 3.1M | 2.9M | 2.9M | 3.1M |
Celldex Therapeutics Investors Sentiment
The influence of Celldex Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Celldex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Celldex Therapeutics' public news can be used to forecast risks associated with an investment in Celldex. The trend in average sentiment can be used to explain how an investor holding Celldex can time the market purely based on public headlines and social activities around Celldex Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Celldex Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Celldex Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Celldex Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Celldex Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Celldex Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Celldex Therapeutics' short interest history, or implied volatility extrapolated from Celldex Therapeutics options trading.
Pair Trading with Celldex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celldex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celldex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Celldex Stock
| 0.52 | MRKR | Marker Therapeutics | PairCorr |
| 0.41 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Celldex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celldex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celldex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celldex Therapeutics to buy it.
The correlation of Celldex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celldex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celldex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celldex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Revenue Per Share 0.142 | Quarterly Revenue Growth 1.561 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.